TISIDB

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Cell projection, growth cone Cell projection, axon Cell projection, dendrite. Note=Colocalized with SHTN1 in close apposition with actin filaments in filopodia and lamellipodia of axonalne growth cones of hippocampal neurons (By similarity). In neurons, detected predominantly in axons and cell body, weak localization to dendrites (PubMed:20621658).
Domain	PF13882 Bravo-like intracellular region PF00041 Fibronectin type III domain PF07679 Immunoglobulin I-set domain
Function	Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors. During brain development, critical in multiple processes, including neuronal migration, axonal growth and fasciculation, and synaptogenesis. In the mature brain, plays a role in the dynamics of neuronal structure and function, including synaptic plasticity.

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0007409 axonogenesis GO:0007411 axon guidance GO:0008361 regulation of cell size GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0016049 cell growth GO:0022604 regulation of cell morphogenesis GO:0030307 positive regulation of cell growth GO:0030516 regulation of axon extension GO:0031346 positive regulation of cell projection organization GO:0032535 regulation of cellular component size GO:0045666 positive regulation of neuron differentiation GO:0045773 positive regulation of axon extension GO:0045927 positive regulation of growth GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048675 axon extension GO:0050769 positive regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050772 positive regulation of axonogenesis GO:0050900 leukocyte migration GO:0051962 positive regulation of nervous system development GO:0060560 developmental growth involved in morphogenesis GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0090066 regulation of anatomical structure size GO:0097485 neuron projection guidance GO:1990138 neuron projection extension
Molecular Function	-
Cellular Component	GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction GO:0030424 axon GO:0030426 growth cone GO:0030427 site of polarized growth GO:0033267 axon part GO:0044295 axonal growth cone

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-422475: Axon guidance R-HSA-210991: Basigin interactions R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1266738: Developmental Biology R-HSA-109582: Hemostasis R-HSA-445095: Interaction between L1 and Ankyrins R-HSA-373760: L1CAM interactions R-HSA-437239: Recycling pathway of L1 R-HSA-445144: Signal transduction by L1

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between L1CAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between L1CAM and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24746181	Pancreatic Ductal Adenocarcinoma	Inhibit immunity (T cell function)	Predominantly T-regs but not T-effs showed an increased migration on L1CAM expressing H6c7 and Panc1 cells. Whereas proliferation of T-regs did not change in the presence of L1CAM, T-effs proliferated less, exhibited a decreased CD25 expression and an increased expression of CD69. Moreover, these T-effs exhibited a regulatory phenotype as they inhibited proliferation of autologous T cells. Accordingly, CD4(+)CD25(-)CD69(+) T cells were highly abundant in PDAC tissues compared to blood being associated with nodal invasion and higher grading in PDAC patients.

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of L1CAM in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of L1CAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.376	0.68
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.058	0.572
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.148	0.934
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.08	0.911
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.647	0.726
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.995	0.65
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.534	0.526
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.231	0.886
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.837	0.64
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.554	0.669
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.645	0.703
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.252	0.478

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of L1CAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of L1CAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of L1CAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by L1CAM. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of L1CAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of L1CAM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between L1CAM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	L1CAM
Name	L1 cell adhesion molecule
Aliases	CD171; HSAS1; SPG1; HSAS; MIC5; antigen identified by monoclonal antibody R1; CAML1; N-CAM-L1; N-CAML1; NCAM ......
Chromosomal Location	Xq28
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting L1CAM collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting L1CAM.

ID	Name	Drug Type	Targets	#Targets
DB00898	Ethanol	Small Molecule	CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNG1, CACNG2, CHRNA10, CHRNA2 ......	52

Browse L1CAM